Outlook Therapeutics Won FDA Approval. Its Stock Still Trades Below Last Month's Offering Price.

This week Outlook Therapeutics CEO Bob Jahr took the company's story to retail investors through the Virtual Investor "Why Now" on-demand conference, one of those pitch formats where small-cap management teams plead their case to whoever clicks play. The pitch writes itself: on July 24 the FDA approved LYTENAVA (bevacizumab-vikg) as the first and only approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration, with 12 years of exclusivity attached.

The stock's reaction is the puzzle. OTLK trades near the bottom of its 52-week range, at roughly 65 cents a share, about a third below the $0.99 combined price that new investors paid for each share-plus-warrant in last month's 55.6-million-share offering. A company that just cleared biotech's hardest regulatory hurdle is cheaper now than it was a month ago for the same asset. The market is not disputing the approval. It is pricing the launch. That gap — and the specific numbers that will resolve it — is what this article is about.

Why the approval was real

Wet AMD is a leading cause of severe vision loss in older adults, and anti-VEGF injections are the treatment. The workhorse has long been Avastin (bevacizumab), a cancer drug used off-label in the eye for two decades because it works and because it costs the system roughly $50–60 an injection versus roughly $1,850–2,000 for Eylea. Off-label means compounding pharmacies draw an intravenous vial into patient syringes — a practice tied to documented endophthalmitis outbreaks from contaminated product, with no FDA oversight of the repackaging step.

LYTENAVA is the same antibody, purpose-built for the eye, made under FDA-regulated manufacturing with its own approved label. That is a genuine quality fix, not a me-too, and the approval was hard-won: three Complete Response Letters dating back to 2023, including a December 30, 2025 rejection over insufficient efficacy evidence, before the company prevailed through the FDA's internal Formal Dispute Resolution process in May and won approval this July.

The market's objection is the economics, not the science

Here is the part the approval cannot fix. The 12-year exclusivity blocks a second branded ophthalmic bevacizumab — it does not stop compounding pharmacies from making their own bevacizumab syringes, and it does not pull off-label Avastin off the shelf. Management says LYTENAVA's list price will land under $500 a vial, roughly ten times the per-dose cost of the standard of care it aims to replace. The bull case is therefore persuasion, not science: swap a cheap, unregulated syringe for an FDA-approved vial on quality, consistency, and liability grounds.

Management's own base case concedes the incumbent is not going away. The $500 million peak-annual-US-sales-by-2030 target assumes compounded bevacizumab stays in the market, biosimilars launch on time, and pricing pressure continues. That is the real stress test: the moat exists in regulatory form and is unproven in commerce, and it has not yet generated a single quarter of adoption data.

The numbers that will decide it

The company is worth roughly $160 million at the current price, with about $166 million of enterprise value. Management's guidance is $50–75 million of total net revenue in the first twelve months after the US launch, scheduled before the end of calendar 2026, with Europe contributing 10–15%. Take the midpoint, $60 million, against ~$166 million of enterprise value, and you get a roughly 2.5x revenue multiple — a specialty-pharma-like price if they hit the guide. The market is clearly pricing a launch that misses.

Two facts blunt that optimism for anyone who commits today. First, the ramp is back-loaded by design: management expects roughly 10% of first-year revenue in the first three months and about half in the fourth quarter, and the permanent J-code reimbursement hook, which management calls a key inflection point for adoption, is not expected until April 2027 (with an HCPCS application due this October 1). The numbers that validate or break the thesis mostly land six to twelve months out.

Second, the financing is a serial story, and it is still running. The company had $11.2 million of cash at June 30 and just raised about $51 million net from the August deal, with SG&A expected to roughly double by year-end. That money funds a launch that has not produced revenue yet. Shareholders recently approved expanding authorized shares to 600 million and authorizing another reverse split — the same machinery the company has used before to stay above the $1 Nasdaq minimum bid — and the stock is sub-$1 again. A further raise before the J-code lands would be a warning, not a shock.

Sell-side context, for what it is worth: the two most bullish targets, $4 from both Brookline Capital and BTIG, come from banks that ran the August offering. H.C. Wainwright sits at Hold with a $1.60 target. Short interest is about 8.7% of shares outstanding. None of that proves anything by itself, but it tells you who is paid to believe.

The honest read, and what "why now" must prove

I would like to hand you the clean contrarian version: market frightened by a milestone everyone underestimated, valuation collapsed, burden of proof shifted to the bears. The evidence does not support that story cleanly. Run the three gates — operating quality, valuation versus growth, moat durability — and LYTENAVA today fails the first (last quarter's net revenue was $9,000 against a reported net loss of $20.3 million, or $10.9 million adjusted), has a moat real in form but unproven in commerce, and is cheap only if management hits guidance it has not begun to earn. When the tests cannot pass this early, the market's skepticism is not obviously wrong.

The market regime sharpens the point. The S&P 500 sits near all-time highs, up more than 12% year to date, and a genuine FDA approval in a strong tape still cannot lift this stock. That is not ignorance working against OTLK; it is discrimination. The marginal investor is looking at the same "first and only" label management markets, doing the same per-dose math, and declining to pay. In a hot market, that silence is information.

None of that makes the company's story false. The approval is real, the exclusivity is real, and the unmet need — an FDA-overseen alternative to compounding — is real. What "why now" must prove, fact by fact, is the conversion: US revenue tracking toward that $50–75 million first-year number against a ~$60 incumbent, an HCPCS application in by October 1, a J-code in April 2027, and no dilutive rescue raise before the ramp shows up. If by mid-2027 the run rate is far under pace, the market's cheap price was correct and the declines were the signal. If the launch compounds, $160 million will look small against a multi-quarter growth curve.

That is the real value of the "why now" question: it forces timing. Right now, the honest answer is that the market and management have placed opposite bets on a launch that has not started. Only quarterly revenue can call it — no on-demand conference slot can.